Aptose Biosciences (APTO) shares gained 51% amid heavy trading after the firm said overnight a Nasdaq hearings panel approved its request for an extension to prove compliance with the exchange's listing requirements.
More than 289.8 million shares traded intraday compared with a daily average of about 1.2 million.
Humacyte (HUMA) said late Thursday the US Food and Drug Administration granted full approval for SYMVESS, a bioengineered human tissue designed to be universally implantable.
Shares rose 32% as intraday trading volume grew to more than 64.3 million from a daily average of about 3.11 million.
Taoping (TAOP) said Friday that the Nasdaq Stock Market confirmed the company was granted an additional 180 calendar days to comply with its minimum bid price requirement through June 16.
Shares increased 29%, with intraday trading volume at over 134.5 million compared with a daily average of about 739,000.
Price: 0.26, Change: +0.09, Percent Change: +51.41
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。